In addition, mutations in KMT2D in PCa were also shown to be associated with aggressive biologic behaviors as well as a poor prognosis [26], which was consistent with the clinical features of MMR-d PCa patients, suggesting that KMT2D mutations may be engaged in the carcinogenesis and progression of MMR-d tumors and that it might be a potential therapeutic target for MMR-d PCa patients. Here, KMT2D is linked to posterior cortical atrophy.